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Introduction: Myotonic Dystrophy Type 1 (DM1) is an autosomal dominant genetic
illness, characterized by a progressive loss of strength. Important deficits in cognitive
functioning and a significant prevalence of psychiatric disorders have been previously
reported.
Methods: A neuropsychological and psychological assessment was carried out in
31 DM1 patients (61% males) in order to measure the cognitive functioning and
explore their personality profiles. The MMSE Mini-Mental State Examination, Frontal
Assessment Battery (FAB), ENB-2 Battery assessing memory (short term, long term and
workingmemory), integration capacities, visual-spatial ability, attention (selective, divided,
shifting/switching) executive functions, praxis, discrimination and logic capabilities
and psychopathology Symptom Check List 90-R (SCL-90-R) were administered. The
neuropsychological and psychological evaluation of DM1 patients was carried out taking
into consideration the clinical parameters (CTG repeat, age at onset, disease duration,
Muscular Impairment Rate Scale (MIRS), Medical Research Council Scale (MRC) and the
Epworth Sleepiness Scales (EPS)).
Results: Regarding psychopathology 19.4% of patients scored a moderate or high level
of symptoms intensity index (GSI), 12.9% reported a high number of symptoms (PST)
and 16.1% reported a high intensity level of the perceived symptoms (PSDI). Fatigue
and daytime sleepiness resulted as being associated with higher levels of psychoticism
(PSY). Only 1 patient reported a severe impairment in the spatial and temporal orientation,
memory, language, praxis, attention and calculation. Longer disease duration was also
associated with cognitive impairment evaluated through ENB-2 (p < 0.05).
Discussions andConclusions: There are indications of the utility of neuropsychological
and psychological screening and support for these patients and their families due to
the link between disease duration and cognitive performances. A proposal of a clinical
protocol, with an illustration of a clinical case report of a family is presented.
Keywords: myotonic dystrophy, neuropsychological assessment, psychological assessment, neuropsychological
functioning, psychological funtioning, patient empowerment
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INTRODUCTION
Myotonic dystrophy type 1 (DM1; OMIM #160900) is a
multisystemic neuromuscular disorder, which represents the
most common form of muscular dystrophy in adults (1). DM1
is an autosomal dominant disease caused by an expansion of
unstable CTG repeats located within the 3′-UTR of the dystrophia
myotonica protein kinase (DMPK) gene. Mutant transcripts
contain the triplet repeats form RNA hairpins that accumulate
as foci in cell nuclei (2–4). These toxic transcripts are thought
to sequester alternative splicing regulators leading to splicing
defects that are considered the primary cause of DM1 symptoms
(5). DM1 patients suffer from muscle wasting, weakness, and
myotonia but also from heart conductions defects and central
nervous system alterations (1). An important characteristic of
DM1 that can influence adults and children at birth (congenital
DM1, CDM) or during childhood is anticipation, with the
aggravation of the disease severity and onset at an earlier
age through successive generations. Five main categories in
which DM1 patients can be divided into have been identified
by the IDMC—International Myotonic Dystrophy Consortium
(6); “congenital, childhood-onset, juvenile, adult-onset, and late
onset/asymptomatic.” In each one of these five forms, specific
clinical features and management problems are described, and
there is a distinction from each other based on the prevalence
of the main symptoms and apparition profiles.
It is well-known that brain involvement results in cognitive
and psychiatric dysfunction, which have an important impact on
patient quality of life (QoL) (7–9). Neurocognitive dysfunction
such as intellectual disabilities, reduced IQ-values, speech
and language delay, deficit in visuospatial and/or visuo-
constructive skills is a hallmark of the childhood forms of
DM1 (infantile and juvenile onset forms) (8, 10–14). This
dysfunction is comprehensive of neuropsychiatric problems,
such as predominantly inactive subtype of attention deficit
hyperactive disorders or autism spectrum disorders (11, 12).
The juvenile form is characterized by school and problems
with peers and is often under-recognized. These childhood
forms of DM1 have to be considered as a central nervous
system (CNS) disease rather than a muscular or systemic
disease (15). In the adult-onset form of DM1, several studies
have described selective impairments in executive function,
visuospatial function, processing speed, and attention (8,
16–18). Characteristic personality patterns and emotional
disturbances including fatigue, daytime sleepiness, depression,
and apathy have also been reported in DM1 patients (19–
21). DM1 patients have a clear age-related decline of cognitive
functions as demonstrated through detailed neuropsychological
studies, linguistic levels, praxis evaluations, and executive task
evaluations. Two recent longitudinal studies have reported a
cognitive decline especially for verbal memory, attention, visuo-
spatial construction, and processing speed (22, 23) reinforcing
the previous observation of Sansone et al. (17) who observed
a progression of frontal cognitive impairment. The level of
decline does not tend to correlate with either the number
of CTG repeats or the severity of muscle weakness (16, 22,
23). These studies give support for proposals on a possible
degenerative brain process (24). Recently, a review on central
nervous system involvement, highlighted the wide phenotype
and variable cognitive involvement that may occur in myotonic
dystrophies (25).
In a recent study aimed to describe the psychological
characteristics of a large cohort of patients with DM1 in Canada,
it has been reported that DM1 patients are at high risk of
developing a psychiatric disorder (26). Moreover, psychological
traits differ across phenotypes, with the most severe phenotype
tending to show more severe psychological symptoms. High
levels of anxiety and low esteem are associated with lower levels
of education and higher repetition of CTG (26). The literature
about DM1 patient population highlights the predominance of
paranoid together with aggressive traits (27). Furthermore, a
clinically significant personality impairment, with dependent and
paranoid personality patterns has been found and this, in turn,
may decrease QoL (28).
Advanced MRI studies demonstrated across the brain a
widespread white matter disruption and a multifocal gray matter
volume loss by using various single MRI techniques, including
diffusion tensor imaging and voxel-based morphometry,
with correlations found between corresponding quantitative
MRI parameters and triplet expansion, neuropsychological
tests, and the severity of muscular involvement (24, 29–37).
Abnormal patterns of brain connectivity have also been
reported in DM1 patients and have been demonstrated to
account for patients’ personality traits (38–40). A study of
neuroimaging of brain in children and adolescents suggests a
relationship between white matter damage and working memory
(34).
Currently there is still no comprehension regarding the
links existing between pathomolecular mechanisms, genetic
abnormalities and CNS involvement. It is vital to identify the
adequate biomarkers of brain involvement in DM1 as CNS
outcomemeasures are needed for upcoming gene therapy clinical
trials (19, 25, 41, 42).
To date there is no cure or specific treatment for DM1
and treatment is aimed at managing symptoms of the disease,
such as Mexiletine for myotonia and Modafinil for excessive
daytime sleepiness. However, new therapeutic approaches based
on pathogenic mechanisms at RNA or DNA level may become
feasible in the near future
Currently, the best that can be done for DM1 patients is
to give them the best care and clinical follow up, merging it
with psychological assistance and support in order to prevent
alienation. It is well-established that chronic diseases present
challenges to health-related quality of life, an individual’s
perceived physical and mental well-being. Rare diseases may also
create additional threats to quality of life due to poor access to
information, treatment and support, combined with high levels
of stigma. Psychotherapy can help not only this kind of patients,
but also their families, to learn new behaviors and ways of coping
with the symptoms of the disease.
In 2012 the OPTIMISTIC study (Observational Prolonged
Trial In Myotonic Dystrophy type 1 to Improve Quality of
Life–Standards, a Target Identification Collaboration), a project
founded by the European Commission, coordinated by the
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Netherlands and involving collaborative partners from France,
Germany and United Kingdom, was launched (43).
It was a multi-center, randomized trial, designed to evaluate,
as primary objective, the effect and the maintenance of a
tailored behavioral change intervention comprising cognitive
behavioral therapy including graded exercise training against
standard patient management on participation for severe fatigue,
as measured by the DM1-Active scale (Rasch-built measure of
activity and participation for DM1 people). This innovative study
involved over 200 patients across Europe and represented the
first project extending psychotherapy to a large cohort of DM1
patients. The intervention also involved caregivers.
All the studies carried out until now, give a strong indication
that in DM1 patients, cognitive impairments and psychological
problems can affect their behaviors towardmedical providers and
their access to appropriate care, leading to worse QoL. Thus,
it appears that DM1 patients could obtain benefits improving
patient support, especially social and psychological support, and
by improving communication with patients.
It has been observed in the medical settings that patients
often require more information than they are given from
health professionals, and they feel that they would like to
be more involved in therapeutic procedure (44). In order for
an effective involvement of patients in their care and their
increased engagement, it is essential to enact strategies to
improve their health literacy and put them in a condition
that they feel they have control on their disease (45). For
this to occur it is also important to consider the patient’s
preferences and needs in the medical decision-making process
(46).
In fact, it is also important to take into consideration the
mental dimensions, which make all patients unique, along with
the assessment of their biological and clinical characteristics, in
order to be able to tailor the interventions to them (47). The
more there are efforts to create a patient profile which takes
into consideration as many psychosocial elements as possible, the
more it is possible to give a personalized approach in healthcare,
improving and facilitating the communication between the
physician and the patient (48).
In order to be fully effective, personalized medicine needs
patients to be engaged and informed about their condition, who
are also encouraged to discuss what their various treatment
options are and their consequence (49).
The main objective of our study is to carry out a
neuropsychological (through ENB-2 battery, MMSE, FAB)
and psychological assessment (through SCL-90-R) of patients
diagnosed with DM1 in order to measure the cognitive
functioning and explore the personality profiles of these
patients (50) in order to have a general picture of the
cognitive and psychological functioning of Italian DM1
patients. Based on the outcomes, a secondary objective is to
envisage a neuro-rehabilitation and psychological support
program.
On the basis of the Outcomes Measures in Myotonic
Dystrophy type 1 (OMMYD-1) for our study we used
neuropsychological tests and self-report symptom questionnaires
that found consensus among scientific community and measure
the same abilities (19)1. Based on the Canadian experience
(26), the Clinical Psychology Service of IRCCS Policlinico San
Donato has set up an assessment protocol aimed to describe
the neuropsychological and psychological characteristics of
DM1 patients and to evaluate and create a neuro-cognitive
rehabilitation and psychological support service for the patients
in order to preserve the cognitive reserve. The protocol has been
designed to be administered in a time frame compatible with
patient hospitalization or with their outpatient access to our
Neuromuscular Center.
Due to the limitations of the sampling size, in this
study the correlations between cognitive/frontal functioning
and demographic, medical or psychological symptoms will be
explored. This data will be used to better tailor the psychological
and neuropsychological program which was created for the
patients and their families
The assessment protocol has been tested on a small cohort of
Italian DM1 patients and the psychological support program has
been tested on a family with the father and two sons diagnosed
with DM1 and the mother not affected by DM1.
MATERIALS AND METHODS
The authors analyzed the theoretical background in the current
literature on Myotonic Dystrophy in order to identify the
state of art of patients’ neuropsychological and psychological
characteristics and to design an efficient protocol to be used in
this study.
We conducted a review of current literature using the
methodology explained in Appendix 1. The aim was the analysis
of the available neuropsychological and psychological researches
on DM1 patients and consider a plot of studies, which are
presented in Table 1.
Our research contains an original protocol that investigates
both cognitive and psychopathological domains. The selection
of instruments was based on the review of the current available
literature which was previously described (see Table 1). Our
study focused on the neuropsychological and psychological
aspects of DM1 population. Most of the previous studies focused
on cognitive functioning and its association with the medical
characteristics of the disease, such as disease form or CTG length
(12, 14–16, 18, 22, 23, 27, 30, 40, 50, 53, 58–60, 64, 67–69, 71,
72, 74, 75, 78) and other studies looked at the psychological
characteristics (7, 12, 21, 26–28, 40, 50, 52–54, 56–63, 68–70,
73, 74, 77, 78). The purpose of this research was to investigate
both cognition and a psychological symptomatology association.
We opted for a battery containing screening tests (MMSE, for
a general cognitive screening; FAB for the assessment of the
executive functions) and we decided to go for ENB-2 battery vs.
WAIS, because it is validated on the Italian population and it
offers the advantage of a shorter assessment time (7, 11, 12, 14,
1During the OMMYD-1 Workshop, four neuropsychological tests have been
found as relevant in a clinical trial. These tests are Trail Making Test A and B,
Stroop Color and Word Test, FAS (oral word association), and WAIS-R Block
Design subtest. In our ENB-2 battery, similar tests were used to challenge the same
cognitive areas.
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TABLE 1 | Review of neuropsychological and psychological literature on myotonic dystrophy.
Article Country DM form Sample Investigation areas Materials
Angeard et al. (11) France Childhood form 24 DM1 Neurocognition in childhood MIRS
WAIS-III
Bajrami et al. (51) Turkey All forms 13 DM1 Cognitive functions and
cerebral involvement
MRI scans
MIRS
MMSE (Mini-Mental State Examination)
MoCA (Montreal Cognitive Assessment)
EHI (Edinburgh Handedness Inventory)
WAIS
Buschke Selective Reminding test
(neuropsychological)
FAB (Frontal Assessment Battery)
Baldanzi et al. (52) Italy Adult-onset form 65 DM1, 26 healty
controls
Disease’s awarness MIRS
MRC (Medical Research Council scale)
TIB (Brief Intelligence Test)
BDI-II
STAI-Y2
AES (Apathy Evaluation Scale)
INQoL (Individualized Neuromuscular Quality of Life
Questionnaire)
Neuropsychological cognitive battery:
Immediate and Delayed Recall (IR, DR)
RAVLT
IR, DR of Rey-Osterrieth Complex Figure (ROCF)
Digit span and CBT (Corsi’s block test)
TMT A, B
Stroop Test
FAS
FAB
WSCT
Raven’s progressive matrices (PM47)
Bertrand et al. (26) Canada Mild and adult-onset 200 DM1 (152
adult-conset form, 48
mild-
compromission/late-
adult)
Psychological characteristic SCL-90-R (Symptom Check list-90-Revised)
MIRS (Muscular Impairment Rating Scale)
NEO-FFI (Revised NEO Personality Inventory)
Rosenberg scale (self-esteem)
ASIQ (Adult Suicidal Ideation Questionnaire)
WAIS-R (Wechsler Adult Intelligence Scale-Revised)
Bird et al. (53) USA Adult-onset form 29 DM1 Cognitive functions and
psychological
characteristics
WAIS
Shipley-Hartford Scale [pure verbal misure of
intellectual functions]
MMPI (Minnesota Multiphasic Personality Inventory)
Bungener et al.
(54)
France All except for
congenital form
15 DM1, 14 healty
controls, 11 with FSHD
Psychopathology Semistructured interview DSM-III
MADRS (Montgomery and Asberg)
HDRS (Hamilton depressive scales)
Covi and Tyrer anxiety scales
AT (Abrams and Taylor scale for emotional blunting)
EHD (depressive mood scale)
PAS (the physical anhedonia scale)
SAS (social anhedonia scale)
Cabada et al. (55) Spain Adult-onset form 42 DM1, 42 healthy Cerebral involvement,
cognitive functions and
psychopathological traits
Diffusion tensor imaging
WML (White Matter Lesions)
MRI
Digit Span
TMT-B
WAIS-IV (Letters and numbers)
Cubes of the Barcelona Test Revised
CPT (Continuous Performance Test)
Benton Visual Retention Test
TAVEC (Verbal learning Spain Complutense Test)
Interview for Deterioration in Daily Living Activities in
Dementia
Dysexecutive Questionnaire
HARS
BDI-II
SCL-90-R
(Continued)
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TABLE 1 | Continued
Article Country DM form Sample Investigation areas Materials
Caso et al. (30) Serbia Juvenile and
adult-onset form
52 DM1, 34 controls Cognitive impairment and
cerebral damage
MRI scans
ACE-R (Addenbrooke’s Cognitive
Examination–Revised)
Raven progressive matrices
WAIS
Digit symbol coding Arithmetic subtests
TMT
WCST
WAIS digit span
ACE-R memory subscore
RAVLT
ROCF
ACE-R (Addenbooke’s Cognitive Examination)
visuospatial subscore
ROCF Copy Test
WAIS block design
VOT (Hooper Visual Organization Test)
ACE-R language subscore
BNT (Boston Naming Test)
Colombo et al. (56) Italy Severe form 40 DM, 20 healty
controls
Neuropsychological and
psychiatric test
MMSE
WAIS-R
SADS
SRT (Symptom Rating Test)
Cuthill et al. (57) Canada Not specified 13 DM Depression and anxiety HAM-A (Hamilton Anxiety Rating Scale)
HAM-D (Hamilton Depression Scale)
SDS (Zung Self Rating Scale)
Douniol et al. (12) France Childhood form 28 DM1 Cognitive functions and
psychological symptoms:
hyperactivity, autism,
depression, anxiety,
alexithymia, impulsivity;
sleepiness
WISC-R or WAIS
the SAMUEL (visual–spatial construction abilities)
MINI (Mini-International Neuropsychiatric Interview)
the Dominic-R
the whole ADHD section of the Diagnostic Interview
Schedule for Children IV or Adult ADHD Self-Report
Scale
ASME (Autism Mental Status Examination)
Children’s Depression Inventory or BDI
Spielberger State-Trait Anxiety Inventory
Toronto Alexithymia Scale
Lecendreux (for children) or Epworth
(for adults) scales
Eysenck Impulsivity self-report questionnaire
Echenne et al. (15) France and
Canada
Congenital,
infantile/juvenile form
32 DM1 Longitudinal study over
cognition
WAIS
Ekstrom et al. (58) Sweden Congenital and
childhood form
57 DM1 Autism in childhood forms ADI-R (Autism Diagnostic Interview-Revised)
FTF (The Five to Fifteen) [to assess ADHD]
SCQ (Social Communication Questionnaire)
Griffiths Mental Development Scales, WAIS or WISC
Ekstrom et al., (14) Sweden Congenital and
childhood form
55 DM1 Cognition and adaptive skills Griffiths Mental Developmental Scale
WPPSI-R or WISC-III or WAIS-III
VABS (Vineland Adaptive Behavior Scales)
Franzese et al. (59) Italy Juvenile and
adult-onsetform
28 DM1 Cognition and personality Bender Visual Gestalt Test
Wechsler-Bellevue
Cancellation task
MMPI
Irritability-Depression-Anxiety scales of Snaith,
Constantopoulos, Jardine, and McGuffin
(Continued)
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TABLE 1 | Continued
Article Country DM form Sample Investigation areas Materials
Fujino et al. (7) Japan All except congenital
form
60 DM1 Cognition and quality of life MMSE
WAIS-III
VPTA (Visual Perception Test for Agnosia) [Story
telling subtest]
CAT (Clinical Assessment for Attention)
WCST
FAB
TMT
CAT Position Stroop test
Fluency test
Apathy Scale
ESS
PHQ9 (Patient Health Questionnaire-9)
MFI (Multidimensional Fatigue Inventory)
SRS (Social Responsiveness Scale)
MDQoL (Muscular Dystrophy QoL scale)
Gallais et al. (22) Canada Adult or late-onset form 115 DM1 Cognitive decline in
longitudinal study
MIRS
WAIS-R
CVLT (California Verbal Learning Test)
RCFT
Verbal Fluency
BNT
SCWT
Ruff 2 and 7 Selective Attention Test
Gaul et al. (60) Germany Juvenile, adult and
late-onset form
21 DM1, 21 DM2 Cognition in DM1 and DM2:
depressive symptoms and
fatigue; visuo-construction;
attention; prefrontal
functions
Profile of Mood States
RCFT
Symbol Digit Modalities Test
VF (Verbal fluency)
CAL (Conditional-associative learning)
IGT (Iowa Gambling Task)
Goossens et al.
(61)
Netherland-
Belgium
Juvenile 24 DM1 Psychological
characteristics in childhood
WISC-R
CBCL
Jacobs et al. (62) Belgium Juvenile form 27 DM1 Cognitive functions and
psychopathological
WAIS-III
ASEBA (Achenbach System of Empirically
Based Assessment) questionnaire about behavior
checklist:
YSR, ASR, CBCL and ABCL
Kalkman et al. (63) Netherlands Adult-onset form only 79 DM, 65 FSHD and
73 HMSN-I patients
Psychiatric disorders in
neuromuscular disorders
SCID-I-R (structured clinical interview for DSM-IV
axis I)
BDI
SCL-90
GHQ-12 (General Health Questionnaire-12)
MRC
CIS (Checklist Individual Strength)
Kleberg et al. (64) Sweden Juvenile, adult-onset
and late-onset form
33 DM1, 30 healty
controls
Cognitive functions and
facial memory
RBMT-E (Rivermead Behavioural Memory Test)
Neuropsychological tests:
Block design test
Vocabulary test
RAVLT
RCFT
Laberge et al. (65) Canada Adult-onset form 27 DM1 Sleepiness ESS (Epworth Sleepiness Scale)
DSS (Daytime sleepiness Scale)
CFS (Chalder Fatigue Scale)
Malloy et al. (66) USA All forms 20 MMD, 20 normal
control
Neuropsychological
functions
WAIS-R
WSCT
WAB (Western Aphasia Battery)
Benton’s Facial Recognition
Line orientation
Three dimensional construction tests
Wechsler Memory Scale [Russell revision]
(Continued)
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TABLE 1 | Continued
Article Country DM form Sample Investigation areas Materials
Marchini et al. (67) Italy Not specified 24 DM1, 39 healty
controls
Cognitive functions and
other diseases related to
DM
WAIS
Meola et al. (50) Italy Childhood, juvenile and
Adult-onset form
19 DM2, 21 DM1 Cognitive functions and
psychological
characteristics
SCID (Structured Clinical Interview)
MMSE
Battery:
TMT
WCST
TLT (Tower of London Test)
ST (Stroop test)
Lexical retrieval
Computerized assessment of the multiple aspects
of attentional performance
Modoni et al. (16) Italy Congenital and
adult-onset forms
70 DM1 (10 congenital
form, 60
Adult-onsetadult-onset)
Cognitive functions Neuropsychological battery
MMSE
Subtest WAIS:
RAVLT
Rey-Osterrieth figure recall
Digit Span
Phonological and Semantic Word Fluency
Raven Colored Progressive Matrices
Temporal Rule Induction and SCWT
TMT-B
Palmer et al. (68) USA All (except for
congenital form)
21 DM1 (7 mMD and
14 pMD), 10 normal
controls
Cognition and personality MCMI (Millon Clinical Multiaxial Inventory)
WAIS-R
Wechsler Memory Scale
RCFT
Hooper Visual Organization Test
Stroop A, B
WSCT
Peric et al. (28) Serbia Childhood, juvenile,
and adult-onset form
62 DM1 Personality MIRS
RSPM (Raven’s Standard Progressive Matrices)
MMCI
SF-36 (Short Form Health Survey) [serbian version]
INQoL
Perini et al. (69) Italy Adult-onset 17 DM1, 20 unrelated
normal controls, 10
patients with SMA
Cognitive functions and
psychiatric disorders
WAIS
SADS (Schedule for Affective Disorders and
Schizophrenia)
MDRS (Muscular Disability Rating Scale)
Event–Related Potentials
Prevost et al. (70) Canada All forms 308 subjects (44
carriers of DM1 gene
and 264 non-carriers)
Psychological well-being
after genetic test for DM
Questionnaire:
Subjects were asked to complete items related to
their social, economic and
demographic background, the referring person to
DNA testing, the reasons for testing and the recall of
test result.
PSI (Psychiatric Symptom Index)
Romeo et al. (71) Italy Not specified 50 DM1, 14 DM2, 44
healty subjects
Cognition and brain damage MRI images
MIRS, MRC scale
Raven’s progressive Matrices (PM47)
Stroop (Word, Colour, Colour-Word)
Fluency tests
Wechsler Memory Scale
CBT
RCFT
Rubinsztein et al.
(72)
UK All except for
congenital form
36 DM1 Memory and cognitive
functions
Medical Research Council examination technique.
NART (National Adult Reading Test)
MMSE
RBMT (Rivermead Behavioural Memory Test)
WCST
(Continued)
Frontiers in Neurology | www.frontiersin.org 7 September 2018 | Volume 9 | Article 751
Callus et al. Myotonic Dystrophy Type 1 Neuropsychology
TABLE 1 | Continued
Article Country DM form Sample Investigation areas Materials
Sansone et al. (17) Italy Not specified 56 DM1, 29 DM2
(follow-up: 20 DM1, 13
DM2)
Cognitive decline in
longitudinal study
MRC scale
MMSE
RPM (Raven’s Progressive Colored matrices)
Token test
Digit Span forward and Spatial Span
Story Recall and Rey Recall
RCFT
TMT-A and B,
TEA (Alertness and Divided Attention)
TLT
Sansone et al. (73) Italy Not specified (probably
congenital excluded)
“age- and disease
duration-matched,
moderately-affected,
ambulatory patients”
66 Italian patients with
SMC, skeletal muscle
channelopathies; 422
DM (DM1: 382; and
DM2: 40) as control
group
Quality of Life in
neuromuscular disorders
INQoL
SF-36
MMSE
Serra et al. (40) Italy Childhood and
adult-onset forms
27 DM1, 16 healty
controls
Cognitive functions and
psychological
characteristics; f-MRI
MMPI-2
neuropsychological battery
fMRI
Serra et al. (39) Italy All forms (in particular
adult-onset form)
20 DM1, 18 healty
controls
Cognitive functions and
Theory of Mind
MMSE
MIRS
WAIS-R
RMET (Reading the Mind in the Eyes)
ToMstory tests
fMRI
Sistiaga et al. (27) Spain All except congenital
form
121 DM1, 54 control
subjects
Cognition and personality MCMI-II
WAIS-III
MIRS
ESS
Steyaert et al. (74) Holland
-Belgium
Congenital or juvenile
form
16 DM1 Psychological symptoms
and cognitive functions
WISC-R or WAIS
CBCL (Children’s Behavior Checklist)
Child Depression Scale or BDI (Beck Depression
Inventory)
ADIKA (Diagnostic Interview for Children and
Adolescents) [parent’s interview]
Turnpenny et al.
(75)
UK All forms 55 DM1, 31 healty
controls at risk
Cognitive functions WAIS [short version]
Van Spaendonck
et al. (76)
Netherlands Early adult and adult
MD
26 DM, 25 control
subjects
Cognition MDRS (Muscular Disability Rating Scale)
MRC
Zung depression scale
WAIS
CVLT (California Verbal Learning Test)
Stroop test
TMT B-A
VF
WCST
Winblad et al. (77) Sweden Adult-onset form 46 DM1, 31 healthy
controls, 37 in contrast
group
Psychological
characteristics
TCI (Temperament and Character Inventory)
[Swedish version]
Winblad et al. (18) Sweden Adult form (not mild) 47 DM1 Cognitive functions WAIS-R
FAS (verbal fluency)
RCFT (Rey Complex Figure Test)
SCWT-B (Stroop Color and Word Test B)
RAVLT (Rey Auditory Verbal Learning Test)
WCST (Wisconsin Card Sorting Test)
TMT-A TMT-B (Trail Making Test A and B forms)
(Continued)
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TABLE 1 | Continued
Article Country DM form Sample Investigation areas Materials
Winblad et al. (78) Sweden Adult-onset form 50 DM1, 41 healty
controls
Psychological
characteristics and facial
emotion recognition
POFA (Ekman and Friesen’s Pictures of Facial
Affect)
WAIS-R
RAVLT
RCFT
COWAT (Controlled Oral Word Test);
WCST
CWT (Color Word Test)
TMT
TCI
Winblad et al. (21) Sweden Adult-onset form 31 DM1, 47 subjects in
a clinical contrast group
Psychological symptoms
(depression) and cognitive
functions
BDI (Beck Depression Inventory) [Swedish version]
MIRS
tests:
Vocabulary
FAS
Visual construction
RCFT
Block design
Picture completion
RAVLT
TMT
Digit symbol
Digit span
Spatial span
SCWT
WCST
Winblad et al. (23) Sweden Adult-omset form 37 DM1 Cognitive functions at
follow-up
MIRS
FAS
Arithmetic
Block design
RCFT (Rey Complex Figure Test)
RAVLT
TMT-A, TMT-B
Digit Span
Spatial span
SCWT-B
WCST
15, 18, 22, 26, 27, 30, 35, 39, 51, 53, 56, 58, 61, 62, 66–69, 74, 76,
78).
For the assessment of the psychological characteristics,
we adopted the SCL-90-R, based on the Canadian study
of Bertrand et al. (26); since this test allows to inquire
nine psychological dimensions and not only depression or
anxiety that are used in many other studies (21, 52, 54, 57,
60).
The Clinical Psychology Service of the IRCCS Policlinico
San Donato was activated in August 2016 and successively
a collaboration with the Neurology Unit was established.
A neuropsychological and psychological assessment
research protocol on DM1 patients was reviewed and
approved on the 24th of October by the ethical committee
Ospedale San Raffaele in Milan, Italy (registration number
135/INT/2017) and was conducted according to the
principles expressed in the Declaration of Helsinki, the
institutional regulation and Italian laws and guidelines.
Written informed consents were obtained from the
patients.
Sample Characteristics
In our study, 31 DM1 patients referred to the Neuromuscular
Center of the IRCCS Policlinico San Donato and registered in
the Italian Registry for “Myotonic Dystrophy Type 1 and Type 2”
were enrolled.
The following inclusion criteria were utilized: (i) age equal to
or above 18 years; (ii) patients able to comprehend the conditions
of the study and to participate to the entire duration of the study.
Congenital and infantile form, pregnant patients or women who
are breastfeeding and patients with IQ ≤ 91 were excluded. Only
patients with IQ in the norm or above (IQ 92–109 normal/110–
126 > normal) were enrolled in order for them to be able
to complete the whole neuropsychological and psychological
assessment.
Patients were subdivided according to the five clinical forms
based upon the age of onset as recently proposed by De Antonio
et al. (6): (i) congenital form (onset from birth to 1 month); (ii)
infantile form (onset from >1 month to 10 years); (iii) juvenile
form (onset from 11 to 20 years); (iv) adult form (onset from 21
to 40); v) late onset form (onset after the age of 40 years).
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Patients were categorized according to CTG expansion range:
E1 (51–150), E2 (151–500), E3 (501–1,000), E4 (>1,000) (16).
Muscular impairment was assessed using: (i) Muscular
Impairment Rate Scale (MIRS) between 1 and 5: 1 representing
no muscular impairment and 5 representing severe muscular
weakness; (ii) Medical Research Council Scale (MRC), a standard
muscle power test, which grades on a scale of 0–5 in relation to
the maximum expected for that muscle.
We measured individual daytime sleepiness with the Epworth
Sleepiness Scale (ESS), a self-reported questionnaire that asks the
patient to score (from zero to three) their likelihood of falling
asleep in eight routine life situations. A final score ranging from 0
to 9 is considered normal; a score from 11 to 15 is typical of mild
to moderate sleep apnea; a score of 16 and above is associated
with severe sleep apnea.
Methods
The design of the study is evaluative, observational and
prospective.
The assessment process was conducted by a neuropsychologist
of the Clinical Psychology Service of the IRCCS Policlinico San
Donato. The protocol administration lasted for an average of
90/110min and included the following steps:
- Clinical and Neuropsychological Interview
- Neuropsychological assessment
- Psychological assessment
Clinical and Neuropsychological Interview
The purpose of the interview was to assess the following aspects
of patients: personal history (educational, family, occupational,
cognitive, social, medical, psychological), cognitive disorders,
motivation and apathy, emotion and emotional disorders, self-
control, sense of reality and psychotic type disorders, premorbid
personality, personality modification, disease awareness, impact
of disease on quality of life, family relationships and therapeutic
alliance.
Global Cognitive Functioning Assessment
The Global Cognitive Functional Assessment was carried
out through the administration of the Mini Mental State
Examination (MMSE) (79).
This is a test for the assessment of intellectual and efficiency
disorders and the presence of intellectual impairment. It consists
of thirty items that refer to seven different cognitive areas:
orientation in time, orientation in space, recording of words,
attention and calculation,memory, language, constructive praxia.
The total score is between a minimum of 0 and a maximum of 30
points. A score equal to or <18 indicates a serious impairment of
cognitive skills; a score between 18 and 23 indicates a moderate
to mild impairment, a score of 25 is considered borderline.
Executive Functioning Assessment
The Executive Functioning Assessment was carried out through
the administration of the Frontal Assessment Battery (F.A.B.)
(80).
It is a test for the assessment of the efficiency of executive
functions and analyzes the following cognitive abilities:
conceptualization, shifting/switching, planning, inhibitory
control, sensitivity to interference, environmental autonomy
(81). The cut-off limit for the adjusted score is set at 13.50.
Cognitive Domains Assessment Through
ENB-2 Battery (Italian Version)
The ENB-2 assessment battery offers a qualitative and
quantitative analysis of patient performance and is validated on
the Italian population from 15 to 96 years and has the advantage
of offering a shorter assessment time of cognitive domains.
The battery consists of 16 tests that analyze the following
cognitive areas (82): short, long term and working memory,
integration capacity, visual-spatial research, divided attention
and attention shifting/switching, psychomotor speed, verbal
comprehension, lexical recovery, logical and abstract reasoning,
critical sense, capacity for discrimination, complex copy skill,
praxis, and mental representation.
Psychological Evaluation Through
Symptom Check List 90-R (SCL-90-R)
Similarily to Bertrand et al. (26), we selected the SCL-90-
R questionnaire. It is a self-assessment questionnaire built
to provide a standardized measure of an individual’s current
psychological and/or psychopathological status over to past
week, applicable to normal or psychiatric populations of adults
and adolescents (83). So far there is no evidence of other
Italian studies on patients diagnosed with DM1 where a cross
relation between Neuropsychological tests and SCL-90-R were
performed. The objective in our study was to assess other
psychopathological categories other than anxiety, depression,
irritability and avoidant personality, and with the SCL-90-
R there is also the possibility to take into consideration the
3 symptomatological indexes described hereunder. The nine
primary dimensions investigated are: Somatization, Obsessive-
Compulsive Dimension, Interpersonal Sensitivity, Depression,
Anxiety, Hostility, Phobic anxiety, Paranoid ideation and
Psychoticism.
The clinical information that can be obtained from the
administration of SCL-90-R are also summarized into three
indexes: Global Severity Index (GSI), Index of Disorder of
Positive Symptoms (PST) and the Total Index of Positive
Symptoms (PSDI)
The study of the psychometric properties of the SCL-90-R
has provided satisfactory results for what concerns the internal
coherence of the instrument and its reliability test–retest. Further
studies confirmed the validity of construct and the predictive
validity (Italian adaptation by E. Preti, A. Prunas, I. Sarno and
F. Madeddu) (84).
Mean (and SDs) or median (and 1st and 3rd quartiles)
as more appropriated, were used to describe continuous
variables, while counts and percentage were used for categorical
variables. The normality assumption was checked with the use
of the Shapiro–Wilk test. Continuous parameter of diseases
duration were analyzed using the two-sample Wilcoxon test
for non-normally distributed data. Significance level was set at
P < 0.05.
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The SAS software, version 9.4 (SAS Institute, Inc., Cary, NC)
was used for the analysis.
RESULTS
Sociodemographic, clinical, and psychological characteristics of
DM1 patients are reported in Table 2.
A total of 31 patients with DM1 (19 men and 12 women)
participated in this study. All patients were Italian and 77.4%
were from northern Italy. Patients were classified as having
juvenile (58.1%), adult-onset form (29.0%) and late onset (12.9%)
forms of the disease.
The global cognitive functions screened through the MMSE
were normal in the 96.8% of the entire DM1, only one
patient reported a severe impairment in the spatial and
temporal orientation, memory, language, praxis, attention and
calculation.
Concerning the different specific cognitive domains, assessed
through the ENB-2, it was shown that 80.6% of patients
were in the range of normality and 19.4% were below the
TABLE 2 | Sociodemographic, clinical, and psychological characteristics of DM1 patients.
All DM1 (n = 31) Juvenile DM1 (n = 18) Adult-onset DM1 (n = 9) Late-onset DM1 (n = 4)
Age (years) 37.0 (25.0–50.0) 29.5 (24.0–40.0) 39.0 (36.0–52.0) 55.0 (48.0–58.5)
Gender (% Male) 61 55.6 55.6 100
Age at onset (n) 20.0 (16.0–25.0)* 16.0 (12.0–20.0) 31.0 (25.0–33.0) 43.0 (41.0–45.0)*
Disease duration (years) 14.0 (6.0–24.0) 15.0 (6.0–24.0) 14.0 (5.0–18.0) 8.0 (2.0–14.0)
CTG REPEAT RANGE (n)
E1 (51–150) 2 (6.5%) 0 0 2 (50.0%)
E2 (151–500) 16 (51.6%) 10 (55.6%) 5 (55.6%) 1 (25.0%)
E3 (501–800) 6 (19.4%) 5 (27.8%) 1 (11.1%) 0
E4 (>800) 3 (9.7%) 2 (11.1%) 1 (11.1%) 0
not determined 4 (12.9%) 1 (5.6%) 2 (22.2%) 1 (25.0%)
MIRS 3.0 (2.0–4.0) 3.0 (2.0–4.0) 4.0 (3.0–4.0) 2.0 (1.0–3.5)
MRC 125.0 (112.0–127.7) 125.0 (111.0–128.0) 122.7 (115.0–125.0) 126.0 (112.8–130.0)
Epworth Sleepiness Scale 6.0 (4.0–9.0) 7.0 (6.0–12.0) 6.0 (4.0–7.0) 5.5 (3.0–6.0)
Education (years) 13.0 (8.0–13.0) 13.0 (13.0–13.0) 13.0 (8.0–16.0) 8.0 (8.0–8.0)
% employed 71.0 72.2 66.7 75
% in a relationship 45.0 22.2 66.7 100
ITALIAN REGION
North 24 (77.4%) 12 (66.7%) 8 (88.9%) 4 (100%)
Center 3 (9.7%) 3 (16.7%) 0 0
South 4 (12.9%) 3 (16.7%) 1 (11.1%) 0
MMSE
% in the norm range 96.8 94.4 100 100
ENB-2
% in the norm range 80.6 72.2 88.9 100
FAB
% in the norm range 71.0 61.1 77.8 100
% upper limits of the norm 16.1 22.2 11.1 0
% lower limits of the norm 9.7 16.7 0 0
% deficit 3.2 0 11.1 0
SCL-90-R
% T-scores in the normal range
Global severity index 80.6 83.3 77.8 75.0
Positive symptom total 87.1 88.9 77.8 100
Positive symptom distress index 83.9 88.9 77.8 75.0
Somatization 83.9 83.3 77.8 100
Obsessive-compulsive 90.3 94.4 77.8 100
Interpersonal sensitivity 80.6 83.3 77.8 75.0
Depression 80.6 88.9 66.7 75.0
Anxiety 96.8 100 88.9 100
Hostility 77.4 83.3 55.6 100
Phobic anxiety 90.3 94.4 77.8 100
Paranoid ideation 83.9 83.3 77.8 100
Psychoticism 83.9 88.9 77.8 75.0
*Patients excluded since asymptomatic. Median value (interquartile range).
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norm. The most negatively affected domains were: attention
(25.8%), mental representation (29.0%), praxis (32.3%) and
discrimination (22.6%).
The assessment of executive functions through the Frontal
Assessment Battery (FAB) showed that 77.8% of patients had a
normal frontal functioning and 22.2% had an impairment.
About one fifth of our DM1 patients showed SCL-90-R scores
in the range of “normal” and the same distribution also occurred
among the different DM1 forms.
19.4% of patients showed a moderate-high level of symptoms
intensity index (GSI), 12.9% reported a moderate number of
symptoms (PST) and 16.1% reported a moderate-high intensity
level of the perceived symptoms (PSDI).
In relation to the nine symptomatic dimensions of SCL-90-
R, 16.1% of patients refer moderate-high level of somatization
(SOM), this also emerged during the clinical interview where
patients often reported a strong feeling of uneasiness with their
own body. Three patients (9.7%) showed obsessive-compulsive
symptoms (O-C), others (9.7%) reported phobic anxiety (PHOB)
and only one patient suffered from anxiety (ANX). 19.4% of
the sample had a depressive state (DEP), this percentage is
higher in comparison to the prevalence of depression in the
normal population that stands around 2–5% (85). 19.4% of
patients reported a high level of interpersonal sensitivity (IS), a
typical psychological trait of people who experience feelings of
inadequacy and inferiority with respect to others. Furthermore,
the presence of hostility feelings (HOS in the 22.6%) and
paranoid ideation (PAR in the 16.1%) can be seen as an indicator
of existing relational problems. 16.1% of the sample reported the
presence of psychotic symptoms (PSY) like social isolation and
negative symptoms of schizophrenia.
It has been identified that the disease duration has a clinical
impact on the cognitive performances assessed through the ENB
battery. Patients who obtained results in the normal range of the
ENB have a disease duration median of 6 years (5.0–22.0) vs. 23.5
(18.0–34.0) for those who obtained results below the norm (P =
0.03).
No statistical significance was found for other sample
characteristics, such as % in a relationship, % employed and
Italian region in correlation with ENB (respectively P = 0.66; P
= 0.18; P = 0.11).
This might be due to the small sample size.
Illustrative Case Study
In this paragraph we illustrate a clinical case report of a family
of four people (three diagnosed DM1 and one not affected by
disease): Father, 53 years old, DM1 late onset form; Mother, 50
years old, not affected; Son 1, 25 years old, DM1 juvenile form;
Son 2, 21 years old, DM1 juvenile form (neuropsychological and
psychological data collected during the first visit are available in
Table 3).
This family was selected in order to test a family-centered
psychosocial care program since the family members have always
been involved in the Italian Myotonic Foundation activities, as
well as actively promoting initiatives around the DM1 disease.
Since this family is representing most of the disease forms, it
might be representative of the various ages at disease onset and
the different neuropsychological and psychological functioning
as well as providing examples of different coping capabilities.
We designed a family-centered psychosocial care program in
order to support the well-being of the different members. The
main needs were different and were inferred from the SCL-90-
R results and what emerged from the first clinical interview. The
main objective of family-centered psychosocial care program was
to strengthen the emotional resilience of chronically ill patients
and their families. It aims to enhance a “holistic” treatment of
the patient and the family as “a whole”—that is, from a body
and mind perspective—and the psychosocial development of the
patient and his or her family (86).
Wemet the father twice in order to assess his needs for support
based on the fact that his two sons have also been diagnosedDM1.
It immediately appeared that he had a good awareness of the
disease and its implications as well as a strong resiliency. This
also can be seen in Table 3, where all psychological dimensions
are in the range of absence or normal. His demand for support
was about taking care of his two sons and his wife who was feeling
guilty because she was the only one not affected by the disease.
Son 1 is the most serious case in the family. From the
very first clinical interview a clear picture of psychological pain
and isolation from any social relationship emerged. The patient
had just been left by his girlfriend since she was unable to
cope with his disease and did not see any possible future in
their relationship. He participated to 4 monthly psychotherapy
sessions, in which the topics were the elaboration of the breakup
and disease acceptance. The patient had no cognitive impairment
but scored highly on the following psychopathological traits;
O-C, DEP, PAR, PSY with also a high Global Severity index.
Son 2 demonstrated a high intelligence, with very quick
reaction times and a very positive outlook on life. He only
reported that he felt a bit excluded in the family since everyone
was focused on Son 1 for his serious health conditions. He
participated to five psychological sessions and during the clinical
interviews it emerged that he was basically neglecting the fact
the he was diagnosed DM1. There was a focus on the creation of
awareness by using his strong self-perception as a solid point to
be exploited. In fact, he achieved the best results in the cognitive
performance and did not show any psychopathological traits.
The mother reported a strong sense of guilt for being healthy
and a strong fear of losing her children. In order to protect
them she was not allowing herself to feel any emotion since she
wanted to appear strong and protect them from everything. In
the psychological sessions she was allowed to express her feelings
and to work on the acceptance of the situation.
The following indications were given at an individual level
when it comes to the family dynamics:
- Openly sharing information, emotions and fears In order to
reduce the stress and anxiety level related to DM1, it was
important to provide a clear disease perspective to the patients
and family members in collaboration with the neurologist.
By doing so there was also a verification of the disease
awareness among the different family members through the
psychotherapy sessions;
- Being realistic and coping with what the daily life was
presenting them. It was important to work on a program to
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TABLE 3 | A neuropsychological and psychological assessment of a family.
Cognitive functions Psychological dimensions (SCL-90-R)*
MMSE ENB-2 FAB GSI PST PSDI SOM O-C I-S DEP ANX HOS PHOB PAR PSY
Father 30/30 86 18/18 45 46 45 40 48 40 46 51 46 45 44 46
Son 1 30/30 85 18/18 76 58 88 56 84 64 75 56 60 43 84 85
Son 2 30/30 90 18/18 45 45 47 56 45 42 44 42 48 48 46 42
*T-score : 25–55 (absence/normal), 55–65 (moderate), 65 > (high).
enhance a normal flow of life and step out from a pathological
mode, by living in the here and now;
- Respecting the weaknesses of each other in order to provide
mutual support;
- Psychological support once a month to monitor the situation
by offering a dedicated individual session in order to enable
the patients and their family members to share their fears,
emotions and concerns.
Table 3 indicates the neuropsychological and psychological
results of the family where three members have been diagnosed
with DM1.
The data shown in Table 3 are referring to the
neuropsychological and psychological dimensions assessed
during the first visit of the family members. A follow up
assessment will take place at the end of the psychotherapy
sessions by the end of 2018.
From a clinical observation perspective, we noticed an
improvement of the general mood of son 1 who has developed a
social network, has started socializing and has also started a part-
time job showing an increased awareness and new abilities to
cope with his disease. The improvement of the clinical symptoms
of son 1 is having positive effects on the whole family with
reduced stress for all members and a more supportive family
environment can now be observed. Follow up data will be
available at the end of the year.
DISCUSSIONS AND CONCLUSIONS
Recently in our hospital, the Clinical Psychology Unit of
the IRCCS Policlinico San Donato in collaboration with the
Neurology Unit has developed a battery of tests to evaluate
cognitive assessment, personality traits and depression based on
the results obtained by the Canadian team (26). A small group
of DM1 patients has been tested with the intent to give them
the possibility to access to psychological support other than to
standard clinical care.
Regarding the main objective of this study, our results
show relevant personality impairment in DM1 patients, mainly
hostility, depression and interpersonal sensitivity. These
symptomatic dimensions could be also explained with low
empathy and low collaboration that Winblad measured with the
Temperament and Character Inventory (TCI) (87).
The question which still remains open in our cohort is if these
psychopathological traits were evident before or after the DM1
was diagnosed (88).
In our sample, cognitive impairedDM1 patients have a general
tendency to maximize or minimize their positive symptoms and
as shown in the literature, our DM1 patients tend to have a deficit
in relations due to a low social cognition functioning (ToM,
Theory of Mind) (38).
When it comes to the neuropsychological aspects, we have
noticed that most negatively affected cognitive domains were
praxis, mental representation, attention and discrimination.
Both neuropsychological and psychological impairments
might have an impact on the patients’ perception of quality of life.
In fact, both quality of life and the patients’ actual health, can be
influenced by twomain factors; decisionsmade by physicians and
the patient’s compliance. When a health condition is particularly
serious, decisions regarding a diagnosis or treatment can often
make a difference between life and death. For this reason, it
is relevant for physicians to be able to make the best possible
decisions and that the patients can understand what their clinical
situation is and to follow the medical recommendations given
(46).
In line with with our additional objective the emerging clinical
implications and available data can be used as a basis to provide
neurocognitive rehabilitation programs as well as psychological
support program to DM1 patients and their families. Our study
shows a bigger percentage of cognitive impairment when it comes
to the praxis, mental representation, attention and discrimination
domains, for which we are designing group and individual
rehabilitation programs focused at the improvement of these
functioning. The programwill be available as soon as the research
is completed and a bigger sample is available.
Since the study started last November 2017 and due to
the small current sample size, we decided to describe the
population without other inferential statistical analysis, which
will be integrated in a later phase of the study when more data
will be available.
At the moment we cannot envisage any effective medical
treatment for DM1 patients and the data available in this
research could effectively be used to work on DM1 patients’
empowerment by making use of their cognitive reserve and
stimulate through proper neuro-rehabilitation programs the
main affected cognitive domains and offer psychological support
program. The rehabilitation protocol will focus on attention,
memory, praxis executive functions while on the psychological
side enhance the disease awareness and patients’ coping
strategies.
Our transversal study confirms the results of the longitudinal
trial of Winblad et al. (23), who highlighted a cognitive
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deterioration at follow up time hence confirming the relation
between the disease duration and cognitive performances.
This confirms the core importance of designing an effective
rehabilitation protocol at the end of the data collection.
In these days, patients spontaneously search for information
on the internet, and this might help them get accurate
information but it may also lead them to getting lost on the
web, getting information from unknown sources and inaccurate
information. In order to get an effective involvement of patients
in their care and their increased engagement, it is essential to
enact strategies to improve their health literacy (45). It has been
observed in the medical settings that usually patients require
more information than they are given from health professionals,
and they feel that they would like to be more involved in
therapeutic procedure (44).
This is very much aligned to the innovative P5 approach,
which represents the psycho-cognitive aspects to be considered
in order to empower the patient, increase quality of life
and transform them from a passive recipient into an active
participants in the treatment process (46).
Because of the inherited nature of DM1, a diagnosis in one
individual has implications for other family members, hence the
care system is addressed to the family as a whole. Although
the goal is clear, there are many challenges to proceed in this
direction and it is necessary to create occasions where the patients
have the possibility to be empowered. This means putting the
patients in a condition that they feel they have control on their
disease which in turn leads to an improvement in therapeutic
outcomes (45).
In conclusion, in line with previous studies, there are
indications that also the Italian patients have a high probability
of developing psychiatric disorders. More data are necessary
in order to make inferences about the relationships between
psychosocial, neuropsychological and medical variables. Studies
about the efficacy of interventions specifically established for
these patients and their family members are necessary.
The current limitation is the effect of the small sample
size. The complete analysis with the evaluation of primary and
secondary end points of this study will be available when data
collection is finished.
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